

# ADVISE Trial in People with Alzheimer's Disease

**ADVISE is a Phase 2a clinical trial evaluating CY6463 in patients with Alzheimer's disease and cardiovascular risk factors when compared to placebo over a 3-month treatment period.**

**CY6463** is an investigational **once-daily oral** therapy that has been tested in healthy elderly volunteers and is now being evaluated in people with Alzheimer's disease. Preclinical data suggest CY6463 has the potential to improve overall brain health by reducing inflammation and improving the function of cells and blood vessels in the brain.

## OVER THE COURSE OF PARTICIPATION, THE STUDY WILL MEASURE:



Safety Profile of CY6463



Your Performance on Tests of Memory & Cognition



Markers of Inflammation & Alzheimer's Disease



Markers of Brain Activity

## ARE YOU ELIGIBLE?

You may be eligible if you:

- ✓ Are 60 years of age or older
- ✓ Have Alzheimer's disease
- ✓ Have at least two cardiovascular risk factors (including high blood pressure, diabetes or prediabetes, high cholesterol, and/or are overweight)

## Learn more about the ADVISE trial:

Talk to your doctor

Visit <https://clinicaltrials.gov> (NCT#: 04798989)

Visit TrialMatch at <https://bit.ly/alztrialmatch> (keyword "CY6463")

Call the Alzheimer's Association at **(800)-272-3900**



CY6463 is an investigational therapy and is not approved for the treatment of patients with Alzheimer's disease and cardiovascular risk factors.

More information on CY6463 can be found by visiting: [www.cyclerion.com](http://www.cyclerion.com)

